Invicta Diagnostic Ltd
Incorporated in January 2021, Invicta Diagnostic Limited offers radiology and pathology solutions [1]
- Market Cap ₹ 83.0 Cr.
- Current Price ₹ 66.0
- High / Low ₹ 105 / 60.2
- Stock P/E 15.4
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 56.9 %
- ROE 44.4 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 3.50 | 16.27 | |
| 2.03 | 9.88 | |
| Operating Profit | 1.47 | 6.39 |
| OPM % | 42.00% | 39.27% |
| 1.34 | 1.46 | |
| Interest | 0.01 | 0.03 |
| Depreciation | 0.38 | 0.95 |
| Profit before tax | 2.42 | 6.87 |
| Tax % | 0.83% | 21.54% |
| 2.40 | 5.38 | |
| EPS in Rs | 182.51 | 6.39 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 365% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 124% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 44% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Equity Capital | 0.13 | 8.42 |
| Reserves | 9.30 | 6.39 |
| 0.00 | 0.00 | |
| 1.63 | 2.68 | |
| Total Liabilities | 11.06 | 17.49 |
| 4.59 | 3.85 | |
| CWIP | 0.00 | 0.00 |
| Investments | 4.20 | 8.00 |
| 2.27 | 5.64 | |
| Total Assets | 11.06 | 17.49 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 5.05 | 4.13 | |
| -9.51 | -4.22 | |
| 5.35 | 0.00 | |
| Net Cash Flow | 0.89 | -0.08 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 74.04 | 53.62 |
| Inventory Days | 378.04 | 94.53 |
| Days Payable | 977.68 | 73.53 |
| Cash Conversion Cycle | -525.60 | 74.62 |
| Working Capital Days | -1.04 | 48.91 |
| ROCE % | 56.93% |
Documents
Announcements
-
Commencement of commercial production/operations
30 January 2026 - Primacare started commercial operations at Dadar Centre on 30 Jan 2026; ₹550 lakh investment; PET-CT, CT, pathology services.
-
Acquisition
28 January 2026 - Invicta incorporated three diagnostic LLPs Jan 16–28, 2026; subscribed cash capital ₹51,000, ₹99,000, ₹99,000.
-
Acquisition
28 January 2026 - Three diagnostic LLPs incorporated (Shegaon 20-Jan-2026; two Mumbai 16-Jan-2026); contributions ₹51,000, ₹99,000, ₹99,000.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
19 January 2026 - Certificate under Reg 74(5) for quarter ended Dec 31, 2025: no dematerialisation requests Oct–Dec 2025.
-
Sale or disposal
5 January 2026 - Jan 05, 2026 board approved three LLP incorporations; acquire up to 95% of Vinchurkar for Rs.760 lakhs; partial stake sales.
Business Profile[1]
PC Diagnostics (Invicta) is a diagnostic chain in the Mumbai Metropolitan Region (MMR) offering radiology and pathology services. The company operates 7 diagnostic centres + 1 centralised laboratory, built on a hub-and-spoke model.